Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / TSPO



This biomarker is also known as:
  • translocator protein,
  • PBR,
  • peripheral-type benzodiazepine receptor,
  • Mitochondrial benzodiazepine receptor,
  • PTBR,
  • Peripheral-type benzodiazepine receptor,
  • benzodiazapine receptor (peripheral),
  • PBRS,
  • mitochondrial benzodiazepine receptor,
  • DBI,
  • PBS,
  • IBP,
  • PKBS,
  • pk18,
  • benzodiazepine peripheral binding site,
  • BPBS,
  • MBR,
  • mDRC,
  • translocator protein (18kDa),
  • BZRP,

View in BioMuta


TSPO is a conserved protein found at the outer mitochondrial membrane. TSPO interacts with some benzodiazepines and isoquinoline carboxamides and has different affinities than its endogenous counterpart. TSPO is also involved in the transport of porphyrins and heme.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: Two
QA State: Under Review


The TSPO gene is known to be over-expressed in highly aggressive tumors, especially those of the breast. Increasing levels of the TSPO protein are correlated with more advanced stages of breast cancer. Higher TSPO levels are found in estrogen receptor (ER)-negative breast tumors, compared with ER-positive tumors.

Performance Comment

TSPO was one of numerous potential early detection biomarkers specific to triple-negative breast cancer in multiple pathways identified.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2016 EDRN PI Orientation

The New and Continuing EDRN Principal Investigator Orientation will take place March 14–15, 2016 in Bethesda, Maryland.

Announcement 11/05/2015

Thank you to everyone who made the 29th EDRN Steering Committee Meeting a success. The orientation for new and continuing EDRN PIs will be held Monday-Tuesday, March 14-15, 2016, on the NCI campus. More information will be available later this autumn.

Announcement 06/30/2015

A funding opportunity for a new pancreatic cancer initiative, called The Pancreatic Cancer Detection Consortium (U01), has been released. For more information, please go to /grants/guide/ pa-files/ PAR-15-289.html.